We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Slight Boost Expected in IVD Industry

By LabMedica International staff writers
Posted on 26 Aug 2013
Print article
According to a recent report by healthcare market research publisher Kalorama Information (New York, NY, USA), the US Patient Protection and Affordable Care Act (PPACA) is expected to benefit the IVD and clinical lab test industry to some extent. Sales are expected to rise an extra 1.3% more per year, in the next five years, than would have otherwise been seen without the law.

The Patient Protection and Affordable Care Act (H.R. 3590), passed in 2010 is complex legislation that affects virtually every aspect of health care, and many of its provisions are beginning to take effect now. The overall objective of the PPACA is to expand access to health care coverage for most US citizens and legal residents by requiring individuals to have coverage, and for employers to either provide coverage or pay a penalty that would support coverage from a pool of public funds.

The most significant IVD and clinical lab sales drivers resulting from the PPACA will be an expansion in the number of insured US persons, increased utilization of tests related to nosocomial infections, and new coverage of wellness and prevention programs. Kalorama also noted that the bill contains market restraints as well, and warned that many questions about implementation and future effects remain.

“The reform taketh away from IVD but you could say it ‘giveth’ a little more,” said Bruce Carlson, publisher of Kalorama Information. “Several key provisions of the PPACA, in combination with favorable population demographics, will stimulate IVD product sales. It’s an industry that lives or dies based on test procedure numbers and thus the growth in the number of persons with health care coverage is good news for IVD.”

The Kalorama report contains sales estimates for the historic 2012 period of the IVD market and forecasts are provided through 2022. It then analyzes the impact of various PPACA provisions on the IVD market. The report can be found online (please see Related Links: below).

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare, as well as a full range of custom research services. Kalorama routinely assist the media with healthcare topics.

Related Links:

Kalorama Information
Report: The Impact of Healthcare Reform (PPACA) On the US IVD Industry


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
PSA Test
Human Semen Rapid Test
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.